Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center

NCT05141656 | Unknown DMC

• 1 other identifier: CPOG-CDPC-01
• Study Type: observational
• Target: 20,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a multi-center observational study. The start time for data collection is August 31, 2019. Patients who have been treated at our institution from August 31, 2019, who were diagnosed with pancreatic tumors on or before August 31, 2019 (diagnosed in our hospital or outside hospitals) would all meet the inclusion conditions of the study and be considered enrollment. Patients' baseline and treatment data will be collected under informed concent. The combination of medical big data governance and the leading technology of the big data platform uses real world data to improve the quality and efficiency of pancreatic tumor diagnosis, treatment and scientific research.

Conditions

Pancreatic Neoplasms

Outcome Measures

Primary Outcomes (1)

• OS

  overall survival

  5 years

Secondary Outcomes (2)

• DFS

  5 years

• PFS

  5 years

Study Arms (1)

Single arm

Patients diagnosed as pancreatic tumor will considered to be enrolled regardless of specific pathologic subtypes expect for metastasis of pancreas. Baseline data and treatment information will be collected under fully informed consent.

Other: No intervention will be considered in this study.

Interventions

No intervention will be considered in this study. OTHER

No intervention will be considered in this study.

Single arm

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients diagnosed as tumor of pancreas will all be considered for enrollment.

You may qualify if:

• Age ≥ 18, both male and female;
• Patients with primary pancreatic tumor diagnosed by histology, cytology or imaging;
• Clinical or pathological staging is locally advanced or metastatic pancreatic tumor (newly diagnosed or after surgery and other treatments);
• You can accept or have not received surgery, chemotherapy, radiotherapy, local treatment or traditional Chinese medicine for tumors;
• The subject voluntarily joined the study and signed an informed consent form voluntarily.

You may not qualify if:

• \. Pancreatic tumors are evaluated as metastatic lesions, not primary tumors of the pancreas.

Sponsors & Collaborators

• RenJi Hospital: lead

Study Sites (1)

RenJiH

Shanghai, Shanghai Municipality, 200127, China

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 20, 2021
• First Posted: December 2, 2021
• Study Start: August 31, 2019
• Primary Completion: July 31, 2022
• Study Completion: July 31, 2023
• Last Updated: December 2, 2021

Record last verified: 2021-11

Locations

CN (1)